More than 40% of Americans with estrogen receptor (ER)-low early breast cancer did not receive endocrine therapy, analysis of a national database showed. Omitting endocrine therapy in ER-low breast ...

Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine therapy alone. The monarchE trial showed improved OS and IDFS rates with ...

Highlights in ER-positive breast cancer from SABCS 2025 include key metastatic and early-stage trial results from AMBRE, ...

A novel artificial intelligence (AI) application capable of diagnosing endocrine cancers with speed and accuracy is being presented Sunday at ENDO 2025, the Endocrine Society's annual meeting in San ...

Thyroid cancer is the most common endocrine cancer, affecting more people each year as detection rates continue to rise.

Six-year outcomes from the FROST trial show breast cancer cryoablation achieved low ipsilateral recurrence and high invasive ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Epigenome remodeling, including widespread changes to DNA methylation and 3D chromatin structure, is increasingly recognized as an important mechanism of gene deregulation in cancer. For example, at ...

More than 46% of women with stage 1 or 2 breast cancer chose to continue endocrine therapy after five years, a recent study found. The study, published in the Journal of the National Cancer Institute, ...

Findings from 11 investigational studies include new data in premenopausal women and comparative analyses of BCI Testing to the 21-gene assay “These data reinforce Hologic’s continued commitment to ...